BRPI0911656A2 - formulações de nanopartículas e usos das mesmas - Google Patents
formulações de nanopartículas e usos das mesmasInfo
- Publication number
- BRPI0911656A2 BRPI0911656A2 BRPI0911656A BRPI0911656A BRPI0911656A2 BR PI0911656 A2 BRPI0911656 A2 BR PI0911656A2 BR PI0911656 A BRPI0911656 A BR PI0911656A BR PI0911656 A BRPI0911656 A BR PI0911656A BR PI0911656 A2 BRPI0911656 A2 BR PI0911656A2
- Authority
- BR
- Brazil
- Prior art keywords
- nanoparticle formulations
- nanoparticle
- formulations
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000002105 nanoparticle Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4400608P | 2008-04-10 | 2008-04-10 | |
| US9666408P | 2008-09-12 | 2008-09-12 | |
| PCT/US2009/040281 WO2009126938A1 (en) | 2008-04-10 | 2009-04-10 | Nanoparticle formulations and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0911656A2 true BRPI0911656A2 (pt) | 2015-10-13 |
Family
ID=40785313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0911656A BRPI0911656A2 (pt) | 2008-04-10 | 2009-04-10 | formulações de nanopartículas e usos das mesmas |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20090263483A1 (pt) |
| EP (1) | EP2288340B1 (pt) |
| CN (1) | CN102056596B (pt) |
| AU (1) | AU2009234127B2 (pt) |
| BR (1) | BRPI0911656A2 (pt) |
| CA (1) | CA2721153C (pt) |
| ES (1) | ES2812529T3 (pt) |
| IL (1) | IL208591A0 (pt) |
| MX (1) | MX2010011165A (pt) |
| WO (2) | WO2009126401A1 (pt) |
| ZA (1) | ZA201008045B (pt) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US8137684B2 (en) * | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| AU2003299590B8 (en) | 2002-12-09 | 2010-04-08 | Abraxis Bioscience, Llc | Compositions and methods of delivery of pharmacological agents |
| PT2301531T (pt) * | 2005-02-18 | 2018-07-30 | Abraxis Bioscience Llc | Combinações e modos de administração de agentes terapêuticos e terapia de combinação |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| NZ592132A (en) | 2005-08-31 | 2012-12-21 | Abraxis Bioscience Llc | Composition comprising nanoparticles of docitaxel and a citrate |
| NO345390B1 (no) | 2005-08-31 | 2021-01-11 | Abraxis Bioscience Llc | Preparater omfattende dårlig vannløselige farmasøytiske midler og antimikrobielle midler |
| US20080280987A1 (en) * | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| ES2700074T3 (es) | 2006-12-14 | 2019-02-13 | Abraxis Bioscience Llc | Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano |
| LT2481409T (lt) * | 2007-03-07 | 2018-10-25 | Abraxis Bioscience, Llc | Nanodalelės, apimančios rapamiciną ir albuminą, kaip priešvėžinį agentą |
| EP3326630A3 (en) * | 2007-05-03 | 2018-08-29 | Abraxis BioScience, LLC | Methods and compositions for treating pulmonary hypertension |
| AU2008260447B2 (en) * | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| RU2559570C2 (ru) | 2009-04-15 | 2015-08-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Композиции без приона на основе наночастиц и способы их получения |
| CA2788078A1 (en) | 2010-01-26 | 2011-08-04 | Yissum Research Development Company Of The Hebrew University Of Jerusale M Ltd. | Compositions and methods for prevention and treatment of pulmonary hypertension |
| HUE027749T2 (en) | 2010-03-26 | 2016-10-28 | Abraxis Bioscience Llc | Methods of treating hepatocellular carcinoma |
| NZ703047A (en) | 2010-03-29 | 2016-11-25 | Abraxis Bioscience Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| EP2552415B1 (en) | 2010-03-29 | 2016-09-07 | Abraxis BioScience, LLC | Methods of treating cancer |
| JP6257324B2 (ja) | 2010-06-04 | 2018-01-10 | アブラクシス バイオサイエンス， エルエルシー | 膵臓がんの処置方法 |
| WO2011156119A1 (en) | 2010-06-07 | 2011-12-15 | Abraxis Bioscience, Llc | Combination therapy methods for treating proliferative diseases |
| JP6038123B2 (ja) | 2011-04-28 | 2016-12-07 | アブラクシス バイオサイエンス， エルエルシー | ナノ粒子組成物の脈管内送達およびそれらの使用 |
| CN102408397B (zh) * | 2011-10-19 | 2014-08-20 | 上海贝美医药科技有限公司 | 紫杉烷类衍生物及其制备方法 |
| EP2768514B8 (en) * | 2011-10-19 | 2019-06-19 | Mercator Medsystems, Inc. | Localized modulation of tissues and cells to enhance therapeutic effects including renal denervation |
| PH12014500965A1 (en) | 2011-11-01 | 2014-06-30 | Celgene Corp | Methods for treating cancers using oral formulations of cytidine analogs |
| WO2013085902A1 (en) | 2011-12-05 | 2013-06-13 | The University Of Texas M.D. | Combination therapy methods for treating an inflammatory breast cancer |
| HUE045661T2 (hu) | 2011-12-14 | 2020-01-28 | Abraxis Bioscience Llc | Polimer segédanyagok alkalmazása részecskék liofilizálásához vagy fagyasztásához |
| CN104411324A (zh) | 2012-04-04 | 2015-03-11 | 哈洛齐梅公司 | 使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法 |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| US10744110B2 (en) | 2013-03-12 | 2020-08-18 | Abraxis Bioscience, Llc | Methods of treating lung cancer |
| US9962373B2 (en) | 2013-03-14 | 2018-05-08 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
| TN2016000077A1 (en) * | 2013-09-16 | 2017-07-05 | Astrazeneca Ab | Therapeutic polymeric nanoparticles and methods of making and using same |
| US20150359810A1 (en) | 2014-06-17 | 2015-12-17 | Celgene Corporation | Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10973806B2 (en) | 2015-06-29 | 2021-04-13 | Abraxis Bioscience, Llc | Methods of treating epithelioid cell tumors comprising administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin |
| WO2017053391A1 (en) * | 2015-09-22 | 2017-03-30 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
| US11576895B2 (en) | 2016-01-11 | 2023-02-14 | Epicentrx, Inc | Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone |
| US11531030B2 (en) | 2017-04-21 | 2022-12-20 | Mayo Foundation For Medical Education And Research | Polypeptide-antibody complexes and uses thereof |
| WO2019010447A1 (en) * | 2017-07-07 | 2019-01-10 | Epicentrx, Inc. | COMPOSITIONS FOR PARENTERAL ADMINISTRATION OF THERAPEUTIC AGENTS |
| EP3661513A4 (en) | 2017-07-31 | 2021-07-14 | January Therapeutics, Inc. | ORGANOPHOSPHATE DERIVATIVES |
| KR20200104291A (ko) | 2017-11-06 | 2020-09-03 | 랩트 테라퓨틱스, 인크. | 항암제 |
| CN109813892A (zh) * | 2017-11-18 | 2019-05-28 | 丹阳亿太生物科技发展有限公司 | 盐酸赛庚啶快速时间分辨荧光免疫层析定量检测试纸条 |
| WO2019164593A2 (en) | 2018-01-08 | 2019-08-29 | Epicentrx, Inc. | Methods and compositions utilizing rrx-001 combination therapy for radioprotection |
| JP7534957B2 (ja) | 2018-03-20 | 2024-08-15 | アブラクシス バイオサイエンス， エルエルシー | ｍＴＯＲ阻害剤およびアルブミンのナノ粒子の投与を介して中枢神経系障害を処置する方法 |
| US20190351031A1 (en) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 |
| CN110862410A (zh) * | 2018-08-27 | 2020-03-06 | 深圳福山生物科技有限公司 | 三氟甲基硒化合物及其用途 |
| US11708637B2 (en) | 2019-08-13 | 2023-07-25 | The Regents Of The University Of California | Methods of supporting a graphene sheet disposed on a frame support |
| CN112569240A (zh) * | 2019-09-29 | 2021-03-30 | 四川大学华西医院 | 盐酸氯丙嗪在制备细胞周期素蛋白抑制剂中的用途 |
| JP2022553426A (ja) | 2019-10-28 | 2022-12-22 | アブラクシス バイオサイエンス， エルエルシー | アルブミンおよびラパマイシンの医薬組成物 |
| CN115400115B (zh) * | 2021-05-26 | 2025-01-14 | 石药集团中奇制药技术（石家庄）有限公司 | 多西他赛白蛋白组合物和免疫检查点抑制剂的组合及用途 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4942184A (en) * | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
| US5059699A (en) * | 1990-08-28 | 1991-10-22 | Virginia Tech Intellectual Properties, Inc. | Water soluble derivatives of taxol |
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US6537579B1 (en) * | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US5665383A (en) * | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
| US5650156A (en) * | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
| US6753006B1 (en) * | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US20070117863A1 (en) * | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5362478A (en) * | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
| US6749868B1 (en) * | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6528067B1 (en) * | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| DK0693924T4 (da) * | 1993-02-22 | 2008-08-04 | Abraxis Bioscience Inc | Fremgangsmåde til (in vivo) levering af biologiske materialer og sammensætninger, der er egnede dertil |
| US5665382A (en) * | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
| US5997904A (en) * | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US5536263A (en) * | 1994-03-30 | 1996-07-16 | Lectec Corporation | Non-occulusive adhesive patch for applying medication to the skin |
| US5580899A (en) * | 1995-01-09 | 1996-12-03 | The Liposome Company, Inc. | Hydrophobic taxane derivatives |
| CA2231750C (en) * | 1995-09-12 | 2006-07-11 | The Liposome Company, Inc. | Hydrolysis-promoting taxane hydrophobic derivatives |
| US6107332A (en) * | 1995-09-12 | 2000-08-22 | The Liposome Company, Inc. | Hydrolysis-promoting hydrophobic taxane derivatives |
| US6537539B2 (en) * | 1996-01-11 | 2003-03-25 | Human Genome Sciences, Inc. | Immune cell cytokine |
| US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| US8137684B2 (en) * | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| PT1023050E (pt) * | 1997-06-27 | 2013-12-04 | Abraxis Bioscience Llc | Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização |
| US8853260B2 (en) * | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| WO2000064437A1 (en) * | 1999-04-22 | 2000-11-02 | American Biosciences, Inc. | Long term administration of pharmacologically active agents |
| US6541508B2 (en) * | 1999-09-13 | 2003-04-01 | Nobex Corporation | Taxane prodrugs |
| JP2003521514A (ja) * | 2000-02-02 | 2003-07-15 | フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド | 抗腫瘍剤としてのｃ１０ヘテロ置換アセテートタキサン |
| ITMI20001107A1 (it) * | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| ITMI20020681A1 (it) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina |
| ITMI20020680A1 (it) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
| AU2003299590B8 (en) * | 2002-12-09 | 2010-04-08 | Abraxis Bioscience, Llc | Compositions and methods of delivery of pharmacological agents |
| US20050152979A1 (en) * | 2003-09-05 | 2005-07-14 | Cell Therapeutics, Inc. | Hydrophobic drug compositions containing reconstitution enhancer |
| US8420603B2 (en) * | 2004-05-14 | 2013-04-16 | Abraxis Bioscience, Llc | SPARC and methods of use thereof |
| CN101035905A (zh) * | 2004-08-16 | 2007-09-12 | 自然科技公司 | 用于制备质粒dna的改良大肠杆菌菌株 |
| US8735394B2 (en) * | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| PT2301531T (pt) * | 2005-02-18 | 2018-07-30 | Abraxis Bioscience Llc | Combinações e modos de administração de agentes terapêuticos e terapia de combinação |
| US20090130163A1 (en) * | 2005-02-18 | 2009-05-21 | Abraxis Bio Scoence, Inc. | Drugs With Improved Hydrophobicity For Incorporation in Medical Devices |
| EP1869077A2 (en) * | 2005-02-18 | 2007-12-26 | Abraxis BioScience, Inc. | Q3 sparc deletion mutant and uses thereof |
| US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| AU2006216640A1 (en) * | 2005-02-24 | 2006-08-31 | Elan Pharma International Limited | Nanoparticulate formulations of docetaxel and analogues thereof |
| NO345390B1 (no) * | 2005-08-31 | 2021-01-11 | Abraxis Bioscience Llc | Preparater omfattende dårlig vannløselige farmasøytiske midler og antimikrobielle midler |
| NZ592132A (en) * | 2005-08-31 | 2012-12-21 | Abraxis Bioscience Llc | Composition comprising nanoparticles of docitaxel and a citrate |
| US20080280987A1 (en) * | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| US20100112077A1 (en) * | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| ES2700074T3 (es) * | 2006-12-14 | 2019-02-13 | Abraxis Bioscience Llc | Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano |
| LT2481409T (lt) * | 2007-03-07 | 2018-10-25 | Abraxis Bioscience, Llc | Nanodalelės, apimančios rapamiciną ir albuminą, kaip priešvėžinį agentą |
| EP3326630A3 (en) * | 2007-05-03 | 2018-08-29 | Abraxis BioScience, LLC | Methods and compositions for treating pulmonary hypertension |
| AU2008260447B2 (en) * | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| RU2559570C2 (ru) * | 2009-04-15 | 2015-08-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Композиции без приона на основе наночастиц и способы их получения |
-
2009
- 2009-03-12 WO PCT/US2009/036942 patent/WO2009126401A1/en active Application Filing
- 2009-03-12 MX MX2010011165A patent/MX2010011165A/es active IP Right Grant
- 2009-03-12 AU AU2009234127A patent/AU2009234127B2/en active Active
- 2009-03-12 CA CA2721153A patent/CA2721153C/en active Active
- 2009-04-10 WO PCT/US2009/040281 patent/WO2009126938A1/en active Application Filing
- 2009-04-10 CN CN200980121606.8A patent/CN102056596B/zh active Active
- 2009-04-10 BR BRPI0911656A patent/BRPI0911656A2/pt not_active IP Right Cessation
- 2009-04-10 EP EP09729316.1A patent/EP2288340B1/en active Active
- 2009-04-10 US US12/422,192 patent/US20090263483A1/en not_active Abandoned
- 2009-04-10 ES ES09729316T patent/ES2812529T3/es active Active
-
2010
- 2010-10-10 IL IL208591A patent/IL208591A0/en unknown
- 2010-11-10 ZA ZA2010/08045A patent/ZA201008045B/en unknown
-
2014
- 2014-02-28 US US14/194,140 patent/US20140302157A1/en not_active Abandoned
-
2018
- 2018-01-24 US US15/879,320 patent/US20180289620A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20140302157A1 (en) | 2014-10-09 |
| CN102056596A (zh) | 2011-05-11 |
| AU2009234127A1 (en) | 2009-10-15 |
| ZA201008045B (en) | 2012-03-28 |
| US20180289620A1 (en) | 2018-10-11 |
| CA2721153A1 (en) | 2009-10-15 |
| WO2009126938A1 (en) | 2009-10-15 |
| IL208591A0 (en) | 2010-12-30 |
| WO2009126401A1 (en) | 2009-10-15 |
| CN102056596B (zh) | 2015-05-20 |
| MX2010011165A (es) | 2011-02-22 |
| ES2812529T3 (es) | 2021-03-17 |
| EP2288340A1 (en) | 2011-03-02 |
| AU2009234127B2 (en) | 2015-04-30 |
| US20090263483A1 (en) | 2009-10-22 |
| CA2721153C (en) | 2018-10-02 |
| EP2288340B1 (en) | 2020-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0911656A2 (pt) | formulações de nanopartículas e usos das mesmas | |
| BRPI1014160A2 (pt) | Formulações de nanopartículas e aplicações das mesmas | |
| BRPI1008709A2 (pt) | composições e usos das mesmas. | |
| BRPI0913574A2 (pt) | composição de tratamento de acne compreendendo nanoprata e usos | |
| EP2515946A4 (en) | NANOCONJUGATES AND COMPOSITIONS OF NANOCONJUGATES | |
| BRPI0912213A2 (pt) | preparação cosmética | |
| BRPI0822655A2 (pt) | Implemento e sistema para cuidado oral | |
| BRPI1011404A2 (pt) | mutantes e usos dos mesmos | |
| BRPI0913447A2 (pt) | composição de éster, e, composição para cuidado pessoal. | |
| EP2280645A4 (en) | DEVICE FOR PREPARING SKIN AND BIOPOTENTIAL SENSOR | |
| PL2059223T3 (pl) | Kompozycja do pielęgnacji skóry | |
| EP2487146A4 (en) | hONEYCOMB STRUCTURE | |
| BRPI0719732A2 (pt) | nanopartículas de peptídeo e usos para as mesmas | |
| EP2396342A4 (en) | EXPRESSION OF MUTANT ROS PROTEIN IN CANCERS IN HUMAN BEINGS | |
| BRPI0910874A8 (pt) | composições e métodos para cuidado da pele | |
| ATE544443T1 (de) | Haarpflegezusammensetzung | |
| BRPI0920927A2 (pt) | derivados de azaquinolinona e usos dos mesmos | |
| BRPI0922531A2 (pt) | composições de cuidado doméstico e pessoal | |
| BRPI1009372A2 (pt) | compostos, composição farmacêutica e respectivos usos | |
| BRPI0922691A2 (pt) | conjugados de leptina e análogo de leptina e usos dos mesmos | |
| BRPI0917205A2 (pt) | vacina polivalente | |
| BR112012003844A2 (pt) | vacinas de pttv e diagnóstico | |
| BR112012025270A2 (pt) | "composição de cuidados pessoais" | |
| BRPI1015941A2 (pt) | formulações de comprimido de 3-cianoquinolina e uso das mesmas. | |
| BRPI0921947A2 (pt) | formulações de proteína terapêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |